文献速递白血病淋巴瘤

急性淋巴细胞白血病、慢性淋巴细胞白血病和毛细胞白血病患者的第二原发癌

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.
PubMed 文献 · Br J Haematol · 2019-01-31

基于瑞典家庭癌症数据库的双向分析显示,慢性淋巴细胞白血病(CLL)后20种第二原发癌的相对风险显著升高,其中皮肤原位鳞状细胞癌RR为24.58、浸润性鳞状细胞癌RR为7.63、梅克尔细胞癌RR为14.36、霍奇金淋巴瘤RR为7.16、卡波西肉瘤RR为6.76;急性淋巴细胞白血病(ALL)在髓系肿瘤后RR为15.35;毛细胞白血病(HCL)与非霍奇金淋巴瘤和黑色素瘤呈双向风险升高。CLL和HCL与皮肤癌及其他免疫相关癌的双向风险提示免疫功能障碍可能参与,ALL的治疗可能contributing至多种第二原发癌风险。

要点

  • CLL后20种第二原发癌RR显著升高,皮肤原位鳞癌RR 24.58、浸润性鳞癌RR 7.63。
  • ALL在髓系肿瘤后RR为15.35,治疗可能contributing至多种第二原发癌风险。
  • HCL与非霍奇金淋巴瘤和黑色素瘤呈双向风险升高。

核心结论

  • CLL和HCL与皮肤癌及其他免疫相关癌的双向风险提示免疫功能障碍可能参与。
  • ALL的治疗可能contributing至多种第二原发癌风险。
  • 血液肿瘤后ALL风险升高可能提示骨髓功能障碍。
  • 这些发现可能有助于指导治疗决策和预后评估。

研究设计与样本

  • 基于瑞典家庭癌症数据库的双向分析,计算CLL、ALL和HCL患者中任何第二原发癌的相对风险(RR),以及这些白血病作为第二原发癌的风险。

主要发现

  • CLL后20种第二原发癌RR显著升高,皮肤原位鳞状细胞癌RR为24.58、浸润性鳞状细胞癌RR为7.63、梅克尔细胞癌RR为14.36、霍奇金淋巴瘤RR为7.16、卡波西肉瘤RR为6.76。
  • 15对CLL-癌症组合呈双向风险升高。
  • ALL与4种癌症呈双向风险升高,ALL在髓系肿瘤后RR为15.35。
  • HCL与非霍奇金淋巴瘤和黑色素瘤呈双向风险升高。
  • CLL与不同癌症及HCL与不同癌症的双向关联RR一致性高度显著。

关键数值与推荐

  • CLL后皮肤原位鳞状细胞癌RR 24.58。
  • CLL后浸润性皮肤鳞状细胞癌RR 7.63。
  • CLL后梅克尔细胞癌RR 14.36。
  • CLL后霍奇金淋巴瘤RR 7.16。
  • CLL后卡波西肉瘤RR 6.76。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks (RRs) were calculated for any SPCs in patients with chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and hairy cell leukaemia (HCL) and the risks of these leukaemias as SPCs. After CLL, RRs were significant for 20 SPCs, and high for skin squamous cell cancer (24·58 for in situ and 7·63 for invasive), Merkel cell carcinoma (14·36), Hodgkin lymphoma (7·16) and Kaposi sarcoma (6·76). Conversely, 15 CLL cancer pairs were reciprocally increased. The increased risks were reciprocal for ALL and four cancers. RR for ALL was 15·35 after myeloid neoplasia. HCL showed reciprocally increased RRs with non-Hodgkin lymphoma and melanoma. The concordance between RRs for bi-directional associations between CLL and different cancers, and HCL and different cancers was highly significant. For CLL (also for HCL), the bi-directional risks with skin cancers and other immune-related cancers suggest the probable involvement of immune dysfunction. For ALL, treatment may contribute to risks of multiple SPCs. Increased risk of ALL after haematological neoplasms may indicate bone marrow dysfunction. These findings may help guide treatment decisions and prognostic assessment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zheng G, Chattopadhyay S, Sud A, et al. Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. Br J Haematol. 2019. PMID: 30706458. doi:10.1111/bjh.15777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。